Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
[email protected]

Investor Response:
Ashley Kaplowitz
[email protected]

You May Also Be Interested In

• Evolving Luxury and Intelligence: LUXEED Set to Launch Global Media Drive
• High Impact Awards Announces 2026 Winners in Four Categories in Partnership With USA TODAY
• LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress